Investigational drug · Phase 3
Camlipixant
Also called: BLU-5937
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Refractory Chronic Cough, Cough, Irritable Bowel Syndrome.
Phase 3Last checked: Nov 20, 2026Latest source record: Sep 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
3 still active
All registered trials
9
Any phase or sponsor naming "Camlipixant"
First trial start
2022
Oct 25, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Camlipixant", any sponsor or status.
Conditions studied
As listed on its trial records.
- Refractory Chronic Cough
- Cough
- Irritable Bowel Syndrome
Approved drugs for the same conditions: Irritable bowel syndrome · Rare and genetic disease · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Camlipixant" as an intervention, largest first.
- A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic CoughPivotal-lookingActive, not recruiting
Bellus Health Inc. - a GSK companyIndustry
NCT05600777 · 997 participants · Start Dec 5, 2022 · Primary completion Jun 10, 2026
Drug: BLU-5937; Placebo · For: Cough; Refractory Chronic Cough
Sites: Foley, Alabama; Litchfield Park, Arizona; Phoenix, Arizona · 242 sites in all
- A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic CoughPivotal-lookingCompleted
Bellus Health Inc. - a GSK companyIndustry
NCT05599191 · 957 participants · Start Oct 25, 2022 · Primary completion Dec 17, 2025
Drug: BLU-5937; Placebo · For: Cough; Refractory Chronic Cough
Sites: Jasper, Alabama; Litchfield Park, Arizona; Scottsdale, Arizona · 200 sites in all
- A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)Pivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT07519395 · 420 participants (planned) · Start Apr 8, 2026 · Primary completion Mar 9, 2027
Drug: Placebo; Camlipixant · For: Irritable Bowel Syndrome
Sites: Anniston, Alabama; Guntersville, Alabama; Mobile, Alabama · 114 sites in all
- A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough - China ExtensionPivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT07650084 · 75 participants (planned) · Start Nov 21, 2025 · Primary completion Aug 27, 2027
Drug: BLU-5937; Placebo · For: Refractory Chronic Cough
Sites: Leshan, China; Beijing, China; Changsha, China · 38 sites in all
Bellus Health Inc. - a GSK companyIndustry
NCT05959447 · 45 participants · Start Jul 26, 2023 · Primary completion Oct 13, 2023
Drug: Camlipixant; Dabigatran etexilate and 1 more · For: Cough; Healthy
Sites: Québec, Canada
- Evaluation of the Effect of Rifampin and Rabeprazole on the Pharmacokinetics of CamlipixantCompleted
Bellus Health Inc. - a GSK companyIndustry
NCT05899829 · 42 participants · Start Jun 21, 2023 · Primary completion Aug 8, 2023
Drug: Camlipixant; Rabeprazole and 1 more · For: Cough; Healthy
Sites: Québec, Canada
Bellus Health Inc. - a GSK companyIndustry
NCT06222892 · 32 participants · Start Feb 2, 2024 · Primary completion Dec 17, 2024
Drug: Camlipixant · For: Cough
Sites: Miami, Florida; Orlando, Florida; San Antonio, Texas
- A Study to Investigate the Effect of Food on Camlipixant Concentrations in Healthy ParticipantsCompleted
Bellus Health Inc. - a GSK companyIndustry
NCT06497517 · 14 participants · Start Jul 9, 2024 · Primary completion Aug 22, 2024
Drug: GSK5464714- Camlipixant · For: Cough
Sites: Austin, Texas
GlaxoSmithKlineGSK (GSK)
NCT07684586 · 0 participants · Start Jul 2, 2026 · Primary completion Aug 27, 2027
Drug: Camlipixant · For: Cough
Sites: Nottingham, United Kingdom
Newest research
PubMed records naming it or its code names, newest first.
- ATP-P2X3 Signaling as a Shared Neural Sensitization Pathway in Endometriosis and Irritable Bowel Syndrome: Mechanisms and Therapeutic Implications.
Duong MA, Ramdass PVAK · Biomedicines 2026
- Safety, Tolerability, and Pharmacokinetics of Oral Camlipixant: A Randomized First-In-Human Study Using Single and Multiple Ascending Doses.
Chauret N, Garceau D, Harvey L, et al. · J Clin Pharmacol 2026
- Selective P2X3 versus dual P2X2/3 receptor antagonists in refractory chronic cough: a systematic review and dose-response meta-analysis of randomized controlled trials.
Thirumalai J, Sivakumar I, Sekaran S · Purinergic Signal 2026
- Structure of the human P2X3 receptor reveals the basis for subtype-selective inhibition by sivopixant.
Zhao Z, Wang DP, Zhang X, et al. · PLoS Biol 2026
- Cryo-EM structures of human P2X2/3 heteromer channel reveal the structural basis of ligand selectivity.
Cheng X, Zhang W, Che T, et al. · Sci Adv 2026
- The SOOTHE trial of camlipixant in RCC: a cautionary note on stratification and relevance.
Zeng X · Am J Respir Crit Care Med 2026
Also in development for Refractory Chronic Cough
- HW091077Phase 21 trial
Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. · Refractory Chronic Cough
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from GSK.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.